Business Context and Reporting Period
Company: Rocket Pharmaceuticals, Inc. (RCKT)
Filing Type: Form 8-K (Current Report)
Date of Report: August 21, 2026
Reporting Period: Specific event date (August 21, 2026)
Business Context: The filing discloses the adoption of a new Severance and Change in Control Program and the execution of executive employment agreements and amendments.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation structures and severance terms.
Material Changes
The following material changes regarding corporate governance and compensation were implemented on August 21, 2026:
- Adoption of Severance Program: The Board adopted the "Rocket Pharmaceuticals, Inc. Severance and Change in Control Program," superseding prior arrangements for eligible U.S. employees not covered by other agreements.
- New Executive Agreements:
- CEO (Gaurav Shah, M.D.): New agreement with an annual base salary of $674,856 and a target annual incentive bonus of 60% of base salary.
- General Counsel/CCO (Martin Wilson): New agreement with an annual base salary of $547,313 and a target annual incentive bonus of 45% of base salary.
- Amendment to Existing Agreement: Amendment No. 1 to the employment agreement for Chief Operating Officer Christopher Stevens, modifying severance terms for terminations without Cause or for Good Reason.
Guidance, Outlook, and Risks
Management Commentary: The filing provides no operational guidance, financial outlook, or strategic commentary beyond the description of the new compensation programs.
Risks and Contingencies:
- Severance Contingency: All severance benefits under the new Program and executive agreements are contingent upon the employee executing and not revoking a release of claims in favor of the Company.
- Change in Control Triggers: Enhanced severance benefits (including accelerated bonus payouts and extended salary continuation) are triggered by qualifying terminations occurring within specific windows relative to a Change in Control (typically 3 months prior to and 12 months following).
- Superseding Arrangements: The Board or senior management retains the discretion to approve individual arrangements that supersede the general Program for specific individuals.
Investor Verification Checklist
- Verify the full text of the Severance and Change in Control Program and executive agreements, which are filed as exhibits to the Form 10-Q for the quarter ended September 30, 2026.
- Confirm the specific definitions of "Cause," "Good Reason," and "Change in Control" within the new agreements to understand the precise triggers for enhanced payouts.
- Assess the potential cash impact of the new CEO and General Counsel base salaries ($674,856 and $547,313 respectively) against the company's current cash runway.
- Review the terms of the Christopher Stevens Amendment to understand how it alters his previous compensation structure dated July 7, 2025.